venBio Global Strategic Fund, L.P. 3
3 · Metacrine, Inc. · Filed Sep 15, 2020
Insider Transaction Report
Form 3
Metacrine, Inc.MTCR
venBio Global Strategic Fund, L.P.
10% OwnerOther
Holdings
Series B Convertible Preferred Stock
→ Common Stock (472,250 underlying)Series A Convertible Preferred Stock
→ Common Stock (1,960,784 underlying)Series C Convertible Preferred Stock
→ Common Stock (396,089 underlying)
Footnotes (2)
- [F1]Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") are convertible into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
- [F2]The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.